Nuvectis Pharma Accounts Payable Over Time
| NVCT Stock | USD 5.04 0.24 4.55% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Nuvectis Pharma Performance and Nuvectis Pharma Correlation. Nuvectis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvectis Pharma. If investors know Nuvectis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvectis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.16) | Return On Assets (0.61) | Return On Equity (1.40) |
The market value of Nuvectis Pharma is measured differently than its book value, which is the value of Nuvectis that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvectis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Nuvectis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvectis Pharma's market value can be influenced by many factors that don't directly affect Nuvectis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvectis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvectis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvectis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare Nuvectis Pharma and related stocks such as Replimune Group, Lyra Therapeutics, and Kronos Bio Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REPL | 323 K | 323 K | 323 K | 323 K | 323 K | 323 K | 323 K | 2 M | 7.1 M | 3.4 M | 2.4 M | 3.7 M | 5.4 M | 2.6 M | 3.7 M |
| LYRA | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 1.1 M | 922 K | 3.1 M | 2.6 M | 3.1 M | 2.1 M |
| KRON | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 1.5 M | 4.5 M | 998 K | 5 M | 883 K | 838.9 K |
| GOSS | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 97 K | 2.2 M | 956 K | 7.5 M | 3.2 M | 1.5 M | 5.5 M | 2.9 M |
| OLMA | 116 K | 116 K | 116 K | 116 K | 116 K | 116 K | 116 K | 116 K | 116 K | 935 K | 719 K | 23 K | 374 K | 2.7 M | 2.8 M |
| LRMR | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 7.5 M | 2.6 M | 3 M | 3.6 M | 3.5 M | 2.6 M | 1.7 M | 1.7 M | 1.3 M | 2.4 M |
| CNTA | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 7.3 M | 13.8 M | 11.8 M | 9.3 M |
| OBIO | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 2 M | 4 M | 2.9 M | 2.9 M |
| GLUE | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 7.1 M | 6.6 M | 7.9 M | 11.2 M | 7.9 M |
| NAMS | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 487.1 K | 7 M | 11.9 M | 16.9 M | 10 M |
| IVA | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.9 M | 3.6 M | 4.4 M | 5.4 M | 8.4 M | 7.5 M | 6.9 M | 14.6 M | 19.4 M | 37.7 M | 39.6 M |
| CGEM | 65 K | 65 K | 65 K | 54.7 K | 85.4 K | 156.7 K | 247.9 K | 296 K | 296 K | 934 K | 9.7 M | 3.2 M | 2.7 M | 2.5 M | 2 M |
| CMPX | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 629 K | 1.1 M | 867 K | 3.4 M | 4.1 M | 2.2 M |
| IKNA | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 935 K | 2.1 M | 2.4 M | 2.1 M | 2.1 M | 2.2 M |
| AVTE | 542 K | 542 K | 542 K | 542 K | 542 K | 542 K | 542 K | 542 K | 542 K | 542 K | 612 K | 1.2 M | 2.6 M | 2.4 M | 1.6 M |
| ANEB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 110 K | 380.8 K | 534.5 K | 156.4 K | 260 K |
| HOWL | 633 K | 633 K | 633 K | 633 K | 633 K | 633 K | 633 K | 633 K | 633 K | 633 K | 1 M | 2 M | 1.2 M | 1.3 M | 1.4 M |
| EWTX | 667 K | 667 K | 667 K | 667 K | 667 K | 667 K | 667 K | 667 K | 667 K | 667 K | 1.6 M | 3.8 M | 6.1 M | 4 M | 3.6 M |
| CELC | 261.8 K | 261.8 K | 261.8 K | 261.8 K | 261.8 K | 261.8 K | 331.5 K | 71.9 K | 119.8 K | 142.8 K | 217.4 K | 1.5 M | 2.6 M | 5.1 M | 5.3 M |
| CCCC | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 5.4 M | 5.7 M | 4.5 M | 1.2 M | 1.4 M | 2.6 M |
Nuvectis Pharma and related stocks such as Replimune Group, Lyra Therapeutics, and Kronos Bio Accounts Payable description
An accounting item on the balance sheet that represents Nuvectis Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Nuvectis Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
| Nuvectis Pharma | NVCT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 5.04
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.